CoChat

Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes (RABBIT 2 Trial)

Umpierrez, Guillermo E., Smiley, Dawn, Zisman, Ariel, Prieto, Luz M., Palacio, Andres, Ceron, Miguel, Puig, Alvaro, Mejia, Roberto · 2007 · Diabetes Care

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

OBJECTIVE—We sought to study the optimal management of hyperglycemia in non–intensive care unit patients with type 2 diabetes, as few studies thus far have focused on the subject. RESEARCH DESIGN AND METHODS—We conducted a prospective, multicenter, randomized trial to compare the efficacy and safety of a basal-bolus insulin regimen with that of sliding-scale regular insulin (SSI) in patients with type 2 diabetes. A total of 130 insulin-naive patients were randomized to receive glargine and glulisine (n = 65) or a standard SSI protocol (n = 65). Glargine was given once daily and glulisine before meals at a starting dose of 0.4 units · kg−1 · day−1 for blood glucose 140–200 mg/dl or 0.5 units · kg−1 · day−1 for blood glucose 201–400 mg/dl. SSI was given four times per day for blood glucose >140 mg/dl. RESULTS—The mean admission blood glucose was 229 ± 6 mg/dl and A1C 8.8 ± 2%. A blood glucose target of <140 mg/dl was achieved in 66% of patients in the glargine and glulisine group and in 38% of those in the SSI group. The mean daily blood glucose between groups ranged from 23 to 58 mg/dl, with an overall blood glucose difference of 27 mg/dl (P < 0.01). Despite increasing insulin doses, 14% of patients treated with SSI remained with blood glucose >240 mg/dl. There were no differences in the rate of hypoglycemia or length of hospital stay. CONCLUSIONS—Treatment with insulin glargine and glulisine resulted in significant improvement in glycemic control compared with that achieved with the use of SSI alone. Our study indicates that a basal-bolus insulin regimen is preferred over SSI in the management of non–critically ill, hospitalized patients with type 2 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc07-0295

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Cited by

See all 672

Metadata

Authors
Umpierrez, G. E., Smiley, D., Zisman, A., Prieto, L. M., Palacio, A., Ceron, M., Puig, A., & Mejia, R.
Affiliations
  • Emory University (US)
  • University of Miami (US)
  • Emory University School of Medicine, Atlanta, Georgia
Venue
Diabetes Care
Published
2007-09-01
Volume
30
Issue
9
Pages
2181-2186
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2153098857
Cited by
671
References
30
Citations by year
2026: 17 · 2025: 26 · 2024: 17 · 2023: 22 · 2022: 31 · 2021: 29 · 2020: 34 · 2019: 31 · 2018: 38 · 2017: 33 · 2016: 35 · 2015: 55 · 2014: 50 · 2013: 43 · 2012: 51
FWCI
27.04
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Sanofi
  • National Institute of Diabetes and Digestive and Kidney Diseases (R03DK073190)
  • National Center for Research Resources (M01-RR00039, M01RR000039)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, multiple daily insulin injections, sliding scale insulin, glargine, glulisine, hyperglycemia management, glycemic control, hypoglycemia, hospitalized patients, insulin-naive patients, glycemic targets
MeSH terms
Insulin Glargine, Adult, Aged, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Prospective Studies, Treatment Outcome, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.